TAILIEUCHUNG - Báo cáo y học: "Remission makes its way to rheumatology"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: Remission makes its way to rheumatology. | Sokka and Makinen Arthritis Research Therapy 2010 12 129 http content 12 4 129 EDITORIAL L_ Remission makes its way to rheumatology Tuulikki Sokka 1 and Heidi Makinen2 See related research by Saber etal. http content 12 3 R94 Abstract Remission was a rare event even in the most advanced rheumatology clinics until recent times. However in the early 1990s it was chosen as the treatment goal and the primary outcome measure for the Finnish Rheumatoid Arthritis Combination Therapy FIN-RACo trial which can be considered the beginning of remission s way to rheumatology. In addition to remission in patients with rheumatoid arthritis remission in patients with psoriatic arthritis is now being studied although remission criteria for psoriatic arthritis have yet to be defined. Better treatment results with more active treatment strategies and availability of biologic agents motivate rheumatologists to monitor their patients as part of usual rheumatology care. Remission was once an unusual phenomenon in rheumatology despite references to disease-modifying antirheumatic drugs DMARDs as remission-inducing. In the previous issue of Arthritis Research Therapy the study by Saber and colleagues 1 provides further evidence of remission as a reachable goal in a usual rheumatology clinic. The authors report a DAS28 disease activity score using 28 joint counts remission rate of 58 in psoriatic arthritis patients who were treated with anti-tumor necrosis factor therapy for 12 months. Remission started its eventful and ambitious journey in the 1990s in patients with rheumatoid arthritis RA . It was defined as the treatment goal and the primary outcome measure in the Finnish Rheumatoid Arthritis Combination Therapy FIN-RACo trial 2 in 1993 6 years before the first biologic agent became available. Nonetheless the results of the FIN-RACo trial were amazing 42 of those who received a combination of conventional DMARDs were in remission 2

TỪ KHÓA LIÊN QUAN
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.